Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Amylyx Pharmaceuticals Inc AMLX

Amylyx Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in the discovery and development of treatments for neurodegenerative diseases. The Company is focused on the development and commercialization of its product candidate: AMX0035 for the treatment of Wolfram syndrome and for the treatment of progressive supranuclear palsy, and AMX0114, the Company... see more

Recent & Breaking News (NDAQ:AMLX)

Amylyx Pharmaceuticals, Inc. (AMLX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

Accesswire December 1, 2023

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Amylyx Pharmaceuticals, Inc. - AMLX

Newsfile November 30, 2023

Amylyx Pharmaceuticals, Inc. (AMLX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

Accesswire November 30, 2023

Amylyx Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire November 29, 2023

Amylyx Pharmaceuticals, Inc. (AMLX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

Accesswire November 29, 2023

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Amylyx Pharmaceuticals, Inc. - AMLX

PR Newswire November 28, 2023

Amylyx Pharmaceuticals Appoints Camille L. Bedrosian, MD, as Chief Medical Officer

Business Wire November 28, 2023

RELYVRIO® and AMX0114 Data to be Presented at 34th International Symposium on ALS/MND

Business Wire November 27, 2023

Amylyx Pharmaceuticals, Inc. (AMLX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

Accesswire November 27, 2023

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Amylyx Pharmaceuticals, Inc. - AMLX

Accesswire November 26, 2023

Amylyx Pharmaceuticals, Inc. (AMLX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

Accesswire November 26, 2023

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Amylyx Pharmaceuticals, Inc. - AMLX

Newsfile November 24, 2023

Amylyx Pharmaceuticals, Inc. (AMLX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

Accesswire November 24, 2023

Amylyx Pharmaceuticals, Inc. (AMLX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

Accesswire November 23, 2023

Amylyx Pharmaceuticals, Inc. (AMLX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

Accesswire November 22, 2023

Amylyx Pharmaceuticals to Participate at the 6th Annual Evercore ISI HealthCONx Conference

Business Wire November 21, 2023

Amylyx Pharmaceuticals, Inc. (AMLX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

Accesswire November 21, 2023

Amylyx Pharmaceuticals, Inc. (AMLX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

Accesswire November 20, 2023

Amylyx Pharmaceuticals, Inc. (AMLX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

Accesswire November 19, 2023

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Amylyx Pharmaceuticals, Inc. - AMLX

Newsfile November 17, 2023